Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
<h4>Background</h4>Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an incre...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-03-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002542&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849468769222524928 |
|---|---|
| author | Balachandran Kumarendran Michael W O'Reilly Konstantinos N Manolopoulos Konstantinos A Toulis Krishna M Gokhale Alice J Sitch Chandrika N Wijeyaratne Arri Coomarasamy Wiebke Arlt Krishnarajah Nirantharakumar |
| author_facet | Balachandran Kumarendran Michael W O'Reilly Konstantinos N Manolopoulos Konstantinos A Toulis Krishna M Gokhale Alice J Sitch Chandrika N Wijeyaratne Arri Coomarasamy Wiebke Arlt Krishnarajah Nirantharakumar |
| author_sort | Balachandran Kumarendran |
| collection | DOAJ |
| description | <h4>Background</h4>Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an increased risk of nonalcoholic fatty liver disease (NAFLD) in individuals with PCOS and implicated androgen excess as a potential driver.<h4>Methods and findings</h4>We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, body mass index (BMI)-, and location-matched control women registered from January 2000 to May 2016. In 2 independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n = 71,061) and sex hormone-binding globulin (SHBG; n = 49,625). We used multivariate Cox models to estimate the hazard ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR = 2.23, 95% CI 1.86-2.66, p < 0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR = 2.30, 95% CI 1.16-4.53, p = 0.017 for 3-3.49 nmol/L and HR = 2.40, 95% CI 1.24-4.66, p = 0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR = 4.75, 95% CI 2.44-9.25, p < 0.001 for 20-29.99 nmol/L and HR = 4.98, 95% CI 2.45-10.11, p < 0.001 for <20 nmol/L). Limitations of this study include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and absence of data on laboratory assays used to measure serum androgens.<h4>Conclusions</h4>We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in women with PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered. |
| format | Article |
| id | doaj-art-7fc7d0d5c11047569fdb818e62aabfbf |
| institution | Kabale University |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2018-03-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-7fc7d0d5c11047569fdb818e62aabfbf2025-08-20T03:25:45ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762018-03-01153e100254210.1371/journal.pmed.1002542Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.Balachandran KumarendranMichael W O'ReillyKonstantinos N ManolopoulosKonstantinos A ToulisKrishna M GokhaleAlice J SitchChandrika N WijeyaratneArri CoomarasamyWiebke ArltKrishnarajah Nirantharakumar<h4>Background</h4>Androgen excess is a defining feature of polycystic ovary syndrome (PCOS), which affects 10% of women and represents a lifelong metabolic disorder, with increased risk of type 2 diabetes, hypertension, and cardiovascular events. Previous studies have suggested an increased risk of nonalcoholic fatty liver disease (NAFLD) in individuals with PCOS and implicated androgen excess as a potential driver.<h4>Methods and findings</h4>We carried out a retrospective longitudinal cohort study utilizing a large primary care database in the United Kingdom, evaluating NAFLD rates in 63,120 women with PCOS and 121,064 age-, body mass index (BMI)-, and location-matched control women registered from January 2000 to May 2016. In 2 independent cohorts, we also determined the rate of NAFLD in women with a measurement of serum testosterone (n = 71,061) and sex hormone-binding globulin (SHBG; n = 49,625). We used multivariate Cox models to estimate the hazard ratio (HR) for NAFLD and found that women with PCOS had an increased rate of NAFLD (HR = 2.23, 95% CI 1.86-2.66, p < 0.001), also after adjusting for BMI or dysglycemia. Serum testosterone >3.0 nmol/L was associated with an increase in NAFLD (HR = 2.30, 95% CI 1.16-4.53, p = 0.017 for 3-3.49 nmol/L and HR = 2.40, 95% CI 1.24-4.66, p = 0.009 for >3.5 nmol/L). Mirroring this finding, SHBG <30 nmol/L was associated with increased NAFLD hazard (HR = 4.75, 95% CI 2.44-9.25, p < 0.001 for 20-29.99 nmol/L and HR = 4.98, 95% CI 2.45-10.11, p < 0.001 for <20 nmol/L). Limitations of this study include its retrospective nature, absence of detailed information on criteria used to diagnosis PCOS and NAFLD, and absence of data on laboratory assays used to measure serum androgens.<h4>Conclusions</h4>We found that women with PCOS have an increased rate of NAFLD. In addition to increased BMI and dysglycemia, androgen excess contributes to the development of NAFLD in women with PCOS. In women with PCOS-related androgen excess, systematic NAFLD screening should be considered.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002542&type=printable |
| spellingShingle | Balachandran Kumarendran Michael W O'Reilly Konstantinos N Manolopoulos Konstantinos A Toulis Krishna M Gokhale Alice J Sitch Chandrika N Wijeyaratne Arri Coomarasamy Wiebke Arlt Krishnarajah Nirantharakumar Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. PLoS Medicine |
| title | Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. |
| title_full | Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. |
| title_fullStr | Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. |
| title_full_unstemmed | Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. |
| title_short | Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. |
| title_sort | polycystic ovary syndrome androgen excess and the risk of nonalcoholic fatty liver disease in women a longitudinal study based on a united kingdom primary care database |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002542&type=printable |
| work_keys_str_mv | AT balachandrankumarendran polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT michaelworeilly polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT konstantinosnmanolopoulos polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT konstantinosatoulis polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT krishnamgokhale polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT alicejsitch polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT chandrikanwijeyaratne polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT arricoomarasamy polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT wiebkearlt polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase AT krishnarajahnirantharakumar polycysticovarysyndromeandrogenexcessandtheriskofnonalcoholicfattyliverdiseaseinwomenalongitudinalstudybasedonaunitedkingdomprimarycaredatabase |